Nov 8 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant Pharmaceuticals International revising 2016 full year guidance
* Valeant Pharmaceuticals International sees 2016 adjusted EPS to be $5.30 - $5.50, from previous range of $6.60 -$7.00
* FY2016 earnings per share view $6.44, revenue view $9.89 billion -- Thomson Reuters I/B/E/S
* Valeant reports third quarter 2016 financial results
* Q3 adjusted non-GAAP earnings per share $1.55
* Q3 earnings per share view $1.75 -- Thomson Reuters I/B/E/S
* Q3 revenue $2.48 billion versus I/B/E/S view $2.49 billion
* Sees FY 2016 revenue $9.55 billion to $9.65 billion Source text for Eikon: ID:nPnb7rZ20a Further company coverage: VRX.TO